Icon Plc (ICLR) — 分析摘要
Icon Plc（ICLR）的市值为12.62十亿美元，最近一年的营收同比增长了-0.4%。净利润率为2.8%。当前市盈率为55.0倍。
核心要点
- 营收同比变化-0.4%
- 净利润率2.8%
- 市盈率55.0倍
ICLR的营收增长为-0.4%，市盈率为55.0倍。
Icon Plc (ICLR)
更新 — ET · 来源 POLYGON
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
Debt/EBITDA 为 4.1x — 杠杆偏高
利息保障倍数为 2.2x — 应对盈利下滑空间有限
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
员工人数
40,100
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。